press release-凯发88

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

english 凯发88-凯发vip-娱乐凯发app下载中文繁体

news press release media report

year:

select

press release

18 june 2019

alphamab oncology initiated kn046 phase ib/ii clinical trial in tnbc suzhou, china, june 18, 2019 – alphamab oncology announced that kn046, an innovative pd-l1/ctla-4 bispecific antibody developed by the company has made new progress.
06 june 2019

alphamab oncology initiated kn026 phase ii clinical trial alphamab oncology announced that kn026, an anti-her2 bispecific antibody independently developed by the company, has entered phase ii clinical trial in patients with advanced gastric or gastroesophage...
29 may 2019

alphamab oncology announces completion of us$60 million series b financing suzhou, china, may 28, 2019 - alphamab oncology, a leading biopharmaceutical company dedicated to global development of innovative biologics for cancer therapy, announced today that it has completed a...
20 may 2019

alphamab oncology initiates phase ii clinical trial of kn046 in patients with advanced unresectable or metastatic esophageal squamous cell carcinoma suzhou, china, may 20, 2019 - a phase ii clinical trial to evaluate the efficacy, safety and tolerability of kn046 in patients with advanced unresectable or metastatic esophageal squamous cell carcino...
20 may 2019

kn019’s phase ii clinical study protocol symposium was successfully held in beijing suzhou, china, may 20, 2019 - a phase ii clinical study protocol symposium of kn019, a fusion protein composed of the fc-fragment of a human igg1 immunoglobulin linked to the extracellular domain of c...
17 may 2019

phase i clinical data of kn046, an innovative pd-l1/ctla4 bispecific antibody of alphamab oncology, is to be presented at the 2019 asco annual meeting suzhou, china, may 17, 2019 – alphamab oncology announced today that the phase i clinical trial of kn046 (pd-l1/ctla4 bispecific antibody) has achieved expected results. clinical data will be present...
30 april 2019

alphamab oncology initiated kn046 phase ii clinical trial in nsclc alphamab oncology announced that phase ii clinical trial for non-small cell lung cancer has been launched for kn046, an innovative bispecific antibody developed by the company.
08 march 2019

alphamab oncology reaches a cooperation intention with tot biopharm to develop an innovative combination therapy of kn046 and tab008 suzhou, march 8, 2019 - alphamab oncology and tot biopharm company limited (tot biopharm), both located in suzhou industrial park, jointly announced that they have reached an intention to cooperate an...
25 janurary 2019

alphamab oncology collaborates with hec research institute on the combination therapy of kn046 and ct053 alphamab oncology and hec pharmaceutical group research institute (hec research institute) announced that they will jointly develop the combination therapy of kn046, a pd-l1/ctla-4 bispecific antibody...
04 janurary 2019

alphamab oncology is invited to present at the 37th annual j.p. morgan healthcare conference alphamab oncology, a clinical-stage biopharmaceutical company dedicated to the discovery, development, manufacturing and commercialization of world-class innovative therapeutics for cancer treatment, ...